Compare IQVIA Holdings Inc. Common Stock (IQV) vs Vaxcyte Inc. Common Stock (PCVX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IQVIA Holdings Inc. Common Stock vs Vaxcyte Inc. Common Stock — how do they compare? IQVIA Holdings Inc. Common Stock trades at $265 (market cap $42.91B), while Vaxcyte Inc. Common Stock trades at $67.27 (market cap $10.51B). The key difference: IQVIA Holdings Inc. Common Stock is far larger — about 4.1× Vaxcyte Inc. Common Stock's market cap, and IQVIA Holdings Inc. Common Stock is trading nearer its 52-week high, Vaxcyte Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IQVIA Holdings Inc. Common Stock for 6 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| IQV | PCVX | |
|---|---|---|
Market Cap | $42.91B | $10.51B |
Volume | 1,333,456 | 2,644,694 |
Sector | Health | Health |
52-Week High | $275.02 | $73.82 |
52-Week Low | $156.66 | $40.32 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $57.07B | $9.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IQVIA Holdings (IQV) trades at $260.71, down 0.57% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $284.64. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $3.15 surpassing the $3.03 estimate. Revenue growth is steady, projected at $17.0B for 2026, while profitability metrics like a 23.01% ROE and 8.1% net income margin reflect operational strength. The company continues to innovate, launching new predictive analytics tools for life sciences clients.
The outlook for IQV remains positive, supported by strong earnings performance and analyst optimism, though investors should note valuation multiples above sector averages and debt levels. Key risks include competitive pressures in clinical research services and macroeconomic sensitivity affecting client spending.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IQVIA Holdings Inc. Common Stock
IQVIA provides clinical research, healthcare data, technology, and consulting services to life sciences companies. Its work supports drug development and commercialization.
Read more on IQV →About Vaxcyte Inc. Common Stock
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →
